IE
TBPH icon

Israel Englander’s Theravance Biopharma TBPH Stock Holding History

Israel Englander’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-215,500
Closed -$1.59M – 7369
2021
Q3 		$1.59M Buy
+215,500
New +$2.41M ﹤0.01% 4163

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Israel Englander's TBPH Position: Q2 2026 in Review

Israel Englander opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 115,403 shares worth $1.96M. The stake represents ﹤0.01% of the portfolio and ranks #3838 among its holdings. This is a return to the name: Israel Englander previously reported a position in TBPH as recently as Q4 2025.

Israel Englander first reported a position in TBPH in Q3 2014 and has held it in 35 quarters since. The position peaked at $7.58M in Q4 2022. 178 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Israel Englander held 115,403 shares of Theravance Biopharma worth $1.96M as of Q2 2026.
  • Theravance Biopharma was a new Israel Englander position in Q2 2026.
  • Theravance Biopharma made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3838 holding.
  • Israel Englander first reported a position in Theravance Biopharma in Q3 2014 and has held it in 35 quarters since.
  • Israel Englander's Theravance Biopharma position peaked at $7.58M in Q4 2022.
  • 178 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.